COMBAT - A Combination B-and T-Cell Epitope Vaccine to Futureproof COVID-19 Vaccine
- Funded by National Health and Medical Research Council (NHMRC)
- Total publications:0 publications
Grant number: GA202709
Grant search
Key facts
Disease
COVID-19Start & end year
20222025Known Financial Commitments (USD)
$873,396.17Funder
National Health and Medical Research Council (NHMRC)Principal Investigator
N/A
Research Location
AustraliaLead Research Institution
Griffith UniversityResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
We are proposing a vaccine that contains only safe components of the SARS-CoV-2 virus, yet effectively elicits protective immunity. The vaccine works by inducing antibodies capable of preventing the virus from attaching to lung cells, and killer T cells that destroy virus-infected cells. This highly innovative approach will generate a much needed safe and prophylactic 2nd generation modular vaccine, ideal for “vaccine update†that will have a major impact on health and society more generally.